Fig. 6.
In vivo antitumor activity of NK-92-scFv(FRP5)-ζ cells.
5 × 105 NIH 3T3#3.7 tumor cells stably transfected with oncogenically activated human ErbB2 cDNA were mixed with NK-92-scFv(FRP5)-ζ cells (●), parental NK-92 cells (○) at an E/T ratio of 10:1, or saline (■) and immediately injected subcutaneously into the flanks of CD-1 nude mice. Tumor growth was followed by caliper measurements, and tumor volumes were calculated. The standard deviation is represented by error bars.
